Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Specimen Handling 483pembrolizumab 456Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 315Biopsy 274Cisplatin 270Radiotherapy 244Paclitaxel 229Gemcitabine 226Bevacizumab 214Nivolumab 189fludarabine 184venetoclax 174Drug Therapy 171Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 145Docetaxel 144Radiosurgery 137Standard of Care 136Rituximab 126Pemetrexed 117durvalumab 115atezolizumab 110Leucovorin 110Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ustekinumab × 1 year × Clear all
NCT06807593 2026-03-05

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡